Zilucoplan: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข3 clinical studies cited
- โขOverall evidence level: high
- โข5 research gaps identified
Research Studies
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
Howard JF, Bresch S, Genge A, et al. (2023) โข The Lancet Neurology
Phase 3 RAISE trial evaluating zilucoplan 0.3 mg/kg daily SC vs placebo in 174 anti-AChR antibody-positive gMG patients across 75 sites in Europe, Japan, and North America over 12 weeks.
Key Findings
- MG-ADL score change at week 12: -4.39 zilucoplan vs -2.30 placebo (LSM difference -2.09; P=0.0004)
- TEAEs in 77% zilucoplan vs 70% placebo; most common was injection-site bruising (16% vs 9%)
- No major safety findings; serious TEAEs and serious infections similar between groups
- Rapid onset of benefit with separation from placebo evident by week 1
Limitations: 12-week treatment period; limited to AChR antibody-positive patients; placebo response rate may be influenced by score fluctuation
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study
Howard JF, Bresch S, Farmakidis C, et al. (2024) โข Therapeutic Advances in Neurological Disorders
Ongoing open-label extension study evaluating long-term safety and efficacy of daily SC zilucoplan 0.3 mg/kg in 200 gMG patients who completed qualifying phase 2 or phase 3 studies.
Key Findings
- Median exposure 1.2 years (range 0.11-4.45 years); 94% experienced at least one TEAE
- Most common TEAEs were MG worsening (26%) and COVID-19 (25%)
- Sustained MG-ADL improvement through 60 weeks of treatment
- Favorable long-term safety profile with good tolerability
Limitations: Open-label design without comparator arm; interim analysis with ongoing data collection; selection bias from completion of qualifying studies
Comprehensive review of zilucoplan development milestones, mechanism of action, pharmacokinetics, clinical efficacy, and safety leading to regulatory approvals in Japan, the US, and the EU for gMG.
Key Findings
- First approval in Japan (September 2023), followed by US (October 2023) and EU (December 2023)
- Macrocyclic peptide with dual mechanism: C5 cleavage inhibition and C5b-C6 blockade
- Self-administered daily SC injection offering convenience vs IV C5 inhibitors
Limitations: Review article summarizing existing data; no new primary clinical data presented
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 50+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขHead-to-head comparative trials vs eculizumab or ravulizumab in gMG
- โขEfficacy in MuSK antibody-positive or seronegative myasthenia gravis
- โขLong-term safety data beyond 5 years including meningococcal infection incidence
- โขPotential applications in other complement-mediated diseases (e.g., PNH, NMOSD)
- โขBiomarkers predicting optimal response to zilucoplan therapy
Research Overview#
Zilucoplan has been evaluated in a focused clinical development program for generalized myasthenia gravis (gMG), progressing from phase 2 dose-finding through the pivotal phase 3 RAISE trial to the ongoing RAISE-XT open-label extension. The evidence demonstrates consistent efficacy in improving myasthenia gravis-specific outcomes with a favorable safety profile, leading to regulatory approvals in Japan, the US, and the EU in 2023.
The evidence level is classified as high based on a positive phase 3 RCT published in a top-tier neurology journal, confirmatory long-term data from the open-label extension, and regulatory approvals in three major jurisdictions.
RAISE Trial (Phase 3)#
Howard et al., Lancet Neurology 2023 (PMID 37059508)#
The RAISE trial was a randomized, double-blind, placebo-controlled, phase 3 study conducted at 75 sites across Europe, Japan, and North America. It enrolled 174 adults with anti-AChR antibody-positive generalized myasthenia gravis (MGFA class II-IV).
Study Design:
- Patients randomized 1:1 to zilucoplan 0.3 mg/kg SC daily or matched placebo
- Treatment duration: 12 weeks
- Primary endpoint: Change from baseline in MG-ADL score at week 12
- Enrollment: September 2019 to September 2021
Primary Endpoint Results:
- Zilucoplan: LSM change in MG-ADL -4.39 (95% CI -5.28 to -3.50)
- Placebo: LSM change in MG-ADL -2.30 (95% CI -3.17 to -1.43)
- LSM difference: -2.09 (95% CI -3.24 to -0.95; P=0.0004)
Secondary Endpoints:
- Improvements in QMG (Quantitative Myasthenia Gravis) score
- Benefits evident from week 1, indicating rapid onset of action
- Clinically meaningful improvements across mild-to-severe disease spectrum
Safety in RAISE#
- TEAEs: 77% zilucoplan vs 70% placebo
- Most common TEAE: injection-site bruising (16% zilucoplan vs 9% placebo)
- Serious TEAEs: similar incidence between groups
- Serious infections: similar incidence between groups
- No meningococcal infections during the trial
- No major safety findings or treatment-related deaths
RAISE-XT Open-Label Extension#
Howard et al., Ther Adv Neurol Disord 2024 (PMID 38638673)#
RAISE-XT is an ongoing, multicenter, phase 3 open-label extension study enrolling patients who completed qualifying phase 2 or phase 3 zilucoplan studies.
Study Population:
- 200 patients enrolled
- All received daily self-administered SC zilucoplan 0.3 mg/kg
- Median exposure: 1.2 years (range 0.11-4.45 years) at data cutoff (September 2022)
Efficacy Results:
- Sustained MG-ADL improvement maintained through week 60
- Consistent benefits across the broad AChR-positive gMG population
- Patients who switched from placebo (RAISE) showed improvement upon zilucoplan initiation
Safety Results:
- 94% experienced at least one TEAE
- Most common TEAEs: MG worsening (26%), COVID-19 (25%)
- Favorable long-term safety profile
- Good tolerability with continued daily self-injection
Mechanism of Action Studies#
Preclinical and pharmacological studies have characterized zilucoplan's dual mechanism of C5 inhibition:
- C5 cleavage inhibition: Zilucoplan binds C5 with high affinity and prevents cleavage by C5 convertase, blocking generation of both C5a and C5b
- C5b-C6 blockade: Even if residual C5 cleavage occurs, zilucoplan sterically hinders C5b-C6 interaction, providing a second layer of MAC assembly blockade
- Complement inhibition kinetics: At 0.3 mg/kg daily, approximately 97.5% complement inhibition is achieved by the end of the first week
Evidence Quality Assessment#
| Criterion | Assessment | Details |
|---|---|---|
| Study design | Phase 3 RCT + OLE | Double-blind, placebo-controlled (RAISE) |
| Sample size | 174 (Ph3); 200 (OLE) | Adequate for gMG indication |
| Primary endpoint | Met (P=0.0004) | MG-ADL score improvement |
| Onset of action | Rapid (week 1) | Separation from placebo by week 1 |
| Safety profile | Favorable | ISRs most common; meningococcal risk managed |
| Regulatory outcome | 3 approvals | Japan, US, EU (all 2023) |
| Peer-reviewed publication | Yes | Lancet Neurology 2023 |
Key Research Gaps#
-
Comparative trials: No head-to-head studies vs eculizumab or ravulizumab in gMG, which would clarify relative efficacy and convenience advantages.
-
MG subtypes: Efficacy data limited to AChR antibody-positive patients. Studies in MuSK-positive or seronegative MG are needed.
-
Long-term safety: While RAISE-XT provides encouraging data through 60+ weeks, longer follow-up (5+ years) is needed to characterize rare adverse events including meningococcal infection incidence.
-
Other complement-mediated diseases: Zilucoplan's potential in PNH, neuromyelitis optica spectrum disorder (NMOSD), or other conditions driven by terminal complement activation has not been systematically evaluated.
-
Predictive biomarkers: Whether baseline complement levels, MG severity, or other factors predict response magnitude to zilucoplan therapy.
Related Reading#
Frequently Asked Questions About Zilucoplan
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.